Topic: Brain proteins, microglia and lab models
Plain-language summary
Among 455,306 UK Biobank participants, 37 carried one copy of the APOE Christchurch variant (allele frequency 0.004%). None of the carriers, aged 57 to 82, had developed Alzheimer's or mild cognitive impairment, and carriers had significantly lower apolipoprotein B levels than matched non-carriers, but the sample was too small to test dementia risk directly.
What this study adds
Evidence grade: Early
This is a follow-up (cohort) study of 455,306 participants. Among 455,306 UK Biobank participants, 37 carried one copy of the APOE Christchurch variant and none had developed Alzheimer's or mild cognitive impairment by the data freeze. The sample was too small to directly test dementia risk, so this cannot establish that the variant protects against Alzheimer's.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
He, K. Y., Khramtsova, E. A., Cabrera-Socorro, A., Zhang, Y., Li, S., Sarver, B. A. J., et al. (2023). Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-023-00684-7
Vancouver
He KY, Khramtsova EA, Cabrera-Socorro A, Zhang Y, Li S, Sarver BAJ, et al. Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants. Molecular Neurodegeneration. 2023. doi:10.1186/s13024-023-00684-7. PMID: 38017580.
BibTeX
@article{he2023-38017580,
author = {He, K. Y. and Khramtsova, E. A. and Cabrera-Socorro, A. and Zhang, Y. and Li, S. and Sarver, B. A. J. and Smets, B. and Li, Q. S. and De Muynck, L. and Parrado, A. R. and Lovestone, S. and Black, M. H.},
title = {{Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants}},
journal = {Molecular Neurodegeneration},
year = {2023},
doi = {10.1186/s13024-023-00684-7},
pmid = {38017580},
url = {https://doi.org/10.1186/s13024-023-00684-7}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 12 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- 37 heterozygous carriers (27 female, 10 male) identified from whole-exome (n = 454,756) and whole-genome (n = 141,948) sequencing; allele frequency 0.004%
- No carrier (age 56.6-82.1, median 68.6) had developed AD or MCI by the March 2022 data freeze, including four with parental history of AD
- Apolipoprotein B was significantly lower in carriers than non-carriers (p = 0.004 unadjusted; p = 0.036 after statin adjustment), and apoB/apoA1 ratio was lower (p = 0.047)
- Carriers had a lower Alzheimer's polygenic risk score (p = 0.02), which cannot be attributed to the Christchurch variant itself
Why it matters
Among 455,306 UK Biobank participants, 37 carried one copy of the APOE Christchurch variant and none had developed Alzheimer's or mild cognitive impairment by the data freeze. The sample was too small to directly test dementia risk, so this cannot establish that the variant protects against Alzheimer's.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcohort
- Participants455,306
- Evidence strengthEarly
Limitations
No homozygotes were found, so the original Colombian finding could not be validated; too few carriers overlapped with imaging, metabolomics or proteomics data for analysis; only baseline measurements were used; statin adjustment relied on self-report at baseline and may be incomplete.
How this study scored 51/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 50 of the 98 points we could judge it on, which is 51 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular Neurodegeneration) |
| Journal's citation record | 2 / 4 | Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 2 / 5 | Rated “early” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 4 / 4 | 455,306 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 8 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.6 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 2 / 6 | Cited 1.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Mary Helen Black: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Janssen Research & Development (United States): institution h-index 416 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38017580) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 50 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 50 of the 98 points we could judge it on is 51 out of 100. |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Genetics from nearby years
Also in Genetics
198 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.